KRYS
Research Snapshot
Static fundamentals, valuation context, and investor signals for Krystal Biotech, Inc. (KRYS).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
16.8%
ROIC, 48.5% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 10.0x current ratio
Superinvestors
1
Top: Torray Funds (0.5%)
Strengths to research
- ROIC is strong at 16.8%.
- Free cash flow margin is healthy at 48.5%.
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for KRYS.
Grade F
17
/ 100
Financial Charts
No financial data available for KRYS (annual).
1 superinvestors own KRYS
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Torray Funds Torray Funds | 12,032 | $3M | 0.49% | 0.0% |